LifeStance revenue jumps 26% to $435M as new investors pile in
What's the deal? LifeStance HealthDealroom has a profile for this one. Try Dealroom → reported second-quarter revenue of $435.35 million, up 26.1% year over year and ahead of the $414.58 million analysts expected. The outpatient mental health provider posted earnings of $0.06 per share, double the $0.03 consensus.
Why now? Virtus Advisers LLC bought a new stake of 115,039 shares worth roughly $1,232,000 in the second quarter, according to Holdings Channel.
The company swung to a profit from a loss of $0.01 per share in the same quarter in 2025. It reported a net margin of 3.19% and a return on equity of 3.39%.
What's the endgame? LifeStance operates outpatient mental health clinics across the US. Growing revenue and its shift into profitability suggest the model is gaining traction after years of losses.
Where the stock stands: Shares opened at $12.65 on Friday, near a 12-month high of $12.97 and well above the low of $4.77. The company carries a market capitalisation of $4.91 billion and a debt-to-equity ratio of 0.18.
Analysts have turned more positive. BTIG ResearchDealroom has a profile for this one. Try Dealroom → lifted its price target to $18.00 with a "buy" rating, while KeyCorp, Barclays and Canaccord GenuityDealroom has a profile for this one. Try Dealroom → all raised targets to $13.00. Of the analysts covering the stock, one rates it strong buy and six rate it buy.
The signal: With hedge funds and institutions holding 85.50% of the stock and revenue climbing at double-digit rates, LifeStance is drawing steady investor confidence in the demand for outpatient mental health care.
Read more: Ticker Report
Image credit: Generated with Gemini
